Page 141 - 2022_01-Haematologica-web

Predicting response to IST plus EPAG in SAA
lin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacody- namic cohort analysis. Lancet Haematol. 2017;4(4):e183-e191.
48. Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft- versus-host disease-free survival in
patients undergoing HLA-matched unrelat- ed myeloablative hematopoietic cell trans- plantation. J Clin Oncol. 2017;35(36):4003- 4011.
49. Kennedy VE, Chen H, Savani BN, et al. Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoi- etic cell transplantation based on recipient absolute lymphocyte count. Biol Blood Marrow Transplant. 2018;24(1):150-155.
50. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112(5): 973-980.
51. McCarron M, Osborne Y, Story CJ, Dempsey JL, Turner DR, Morley AA. Effect of age on lymphocyte proliferation. Mech Ageing Dev. 1987;41(3):211-218.
haematologica | 2022; 107(1)
133